NattoPharma with strong growth in the first quarter
Oslo, Norway (30 April 2019)
NattoPharma increased revenues by 41% in the first quarter and delivered a positive adjusted EBITDA of NOK 1,9 million.
“We are pleased to deliver a strong first quarter. We continue to demonstrate our ambition of profitable growth which is a result of the increased focus in the organization in the last two to three years.
In the quarter we continued our investments in future growth and profitability with the synthetic K2 development project, where we anticipate initial results during Q2. We also see increasing demand in the market and are working relentlessly to capture a part of this growth through sales and marketing efforts and product offerings. We believe we are on track to deliver in the upper parts of previous guiding with an annual revenue growth of 30-35% and gross margins of 40-45%”
Financial highlights:
| (mnok) | Q1’19 | Q1’18 | Change | 2018 |
| Product Revenue | 27,8 | 19,8 | 8,0 (+41%) | 101,7 |
| Gross Margin | 44,1% | 41,3% | +2,7% | 43,1% |
| EBITDA (adj.) | 1,9 | 0,4 | 1,5 | 6,7 |
| EBT | -0,4 | -3,5 | 3,1 | 1,8 |
Please find enclosed the Nattopharma Group First Quarter 2019 Report.
For more information, please contact:
Kjetil Ramsøy
CEO, NattoPharma
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Tags: